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Abstract: Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role 
of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve 
the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal 
cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesis-
targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. Here 
we review the role of angiogenesis in the tumorigenesis of colorectal cancer, strategies for targeting angiogenesis, and the clinical 
development of aflibercept.
Keywords: aflibercept, colorectal cancer, angiogenesis, targeted therapy, VEGF, VEGFRwang and Lockhart
20  Clinical Medicine Insights: Oncology 2012:6
Introduction
In the US, colorectal cancer is the third most common 
cancer in both men and women and the second most 
common cause of cancer mortality in both genders 
combined.1 In 2011, it accounted for approximately 
140,000  new  cancer  diagnoses  and  50,000  deaths 
in the US alone.1 Worldwide, more than 1.2 million 
new cases, and more than 600,000 deaths was attrib-
uted to colorectal cancer at the same time.2 There-
fore, colorectal cancer is a prominent global health 
  problem. Approximately  60%  of  colorectal  cancer 
cases are diagnosed at the locally advanced or met-
astatic stage.3 Metastatic colorectal cancer carries a 
poor prognosis, with a 5-year survival rate of approx-
imately 12%.3 Over the past two decades, there have 
been significant advances in the treatment of meta-
static colorectal cancer, one of which is the develop-
ment of agents that target angiogenesis. Incorporation 
of these anti-angiogenic agents into clinical practice 
has led to improvements in progression-free survival 
and overall survival in metastatic colorectal cancer.4 
In this paper, we will review the rationale and recent 
progress in targeting angiogenesis in metastatic col-
orectal cancer, with a special focus on the novel anti-
angiogenesis agent, aflibercept.
Angiogenesis and Tumorigenesis
Angiogenesis  is  the  process  of  new  blood  vessel 
formation. Blood vessels are needed for the supply of 
nutrients and oxygen and the disposal of waste prod-
ucts, and therefore angiogenesis is essential in the 
growth and development of normal tissues as well as 
tumors. It is widely accepted that tumors are unable to 
grow beyond 2–3 mm without blood vessels in vivo.5,6 
Since 1971, when Folkman observed the importance 
of angiogenesis in tumorigenesis, and predicted that 
“antiangiogenesis may provide a form of cancer ther-
apy worthy of serious exploration”, angiogenesis has 
generated intense research interest.5
Angiogenesis  is  a  highly  regulated  and  complex 
process involving a variety of proangiogenic and anti-
angiogenic  factors  and  multiple  signaling  pathways 
that intertwine and regulate each other. In a healthy 
individual, there is a delicate balance between proan-
giogenesis and antiangiogenesis. However, as a tumor 
develops, it often outgrows its vascular supply, thus 
producing a hypoxic environment. Hypoxia switches 
on the hypoxia-inducible factor-1 alpha   system, which 
stimulates  the  production  of  proangiogenic  factors 
in excess of antiangiogenic factors, or the so-called 
“angiogenic switch” phenomenon, leading to patho-
logical  angiogenesis.7,8  One  of  the  main  proangio-
genic pathways is mediated by the vascular endothelial 
growth factor (VEGF) family, composed of six growth 
factors  (VEGF-A,  VEGF-B,  VEGF-C,  VEGF-D, 
VEGF-E, and placenta growth factor) and three recep-
tors (VEGFR-1, VEGFR-2, and VEGFR-3).8
The VEGF receptors are members of the transmem-
brane  tyrosine  kinase  receptor  family.  Each  VEGF 
receptor is composed of several crucial domains, ie, the 
immunoglobulin-like, ligand-binding extramembrane 
domain,  the  transmembrane  domain,  the  juxtamem-
brane  domain,  and  the  intracellular  tyrosine  kinase 
domain (see Fig. 1, modified from figures by Salmon 
et al,8 Cross et al,9 and Kerbel10). Circulating VEGFs 
bind to the corresponding receptors, and activate the 
dimerization of the receptors. Upon dimerization, the 
receptors undergo conformational changes that expose 
ATP binding sites on the intracellular kinase domains, 
resulting in autophosphorylation of the tyrosine resi-
dues of the domains and activation of a cascade of 
downstream signaling transduction pathways.
The function of VEGFR-1 is not yet fully defined. 
Even though VEGFR-1 has at least 10 times stron-
ger affinity for VEGF-A compared with VEGFR-2, 
its  kinase  activity  is  weak.11  VEGFR-1  knockout 
mice die in utero due to increased vascular prolifera-
tion and disorganization.12 However, embryos lack-
ing purely the tyrosine kinase domain of VEGFR-1 
can survive with normal vasculature development.13 
These  findings  indicate  that  VEGFR-1  serves  to 
sequester VEGF-A and negatively regulates the func-
tions of VEGFR-2 pathways.14 On the other hand, 
recent  research  has  further  identified  additional 
roles for VEGFR-1. It has been found to be impor-
tant  in  promoting  angiogenesis  and  the  migration 
of hematopoietic stem cells.15 Therefore, the exact 
role of VEFGR-1 remains unclear and needs further 
investigation.
The interaction between VEGFR-2 and VEGF-A is 
the best characterized ligand-receptor relationship in 
the angiogenesis process. Their interaction initiates a 
variety of downstream signaling pathways, resulting in 
endothelial cell proliferation, differentiation, migration, 
invasion, survival, and increased   endothelial permea-
bility, leading to the sprouting of new blood vessels.14,15 Aflibercept in metastatic colorectal cancer
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Deletion of the VEGFR-2 gene is not compatible with 
life, given that all knockout mice die in utero with 
severe blood vessel deficiencies.16 On the other hand, 
the ligand-receptor interactions between VEGFR-3 and 
VEGF-C and VEGF-D appear to be the most impor-
tant for the formation and migration of the lymphoen-
dothelial system. Mutations in VEGFR-3 are identified 
in rare cases of congenital hereditary lymphedema in 
humans.17 Elevated levels of VEGFR-3 and its ligands 
are found in multiple types of tumors, and are associ-
ated with lymph node metastasis.18
Angiogenesis and Colon Cancer
Studies have shown markedly increased expression of 
VEGF and vascular density in primary colon tumor that 
was associated with metastasis compared with that with-
out metastasis or benign adenoma.19 It was also found 
that the invasive edge of the colon tumor tissue contained 
significantly  higher  vascular  density  than  other  areas 
within the tumor.19 These observations all indicate that 
VEGF expression is crucial in tumor metastasis. VEGF 
expression is also correlated with higher risk of tumor 
recurrence.19,20 Other studies have suggested a potential 
role for VEGF expression as a prognostic factor and 
could  therefore  identify  high-risk  patients  who  might 
benefit from adjuvant chemotherapy in otherwise ambiv-
alent clinical scenarios.21 Prospective studies are needed 
to explore and validate these findings further. Given that 
enhanced angiogenesis has been consistently associated 
with poor outcomes in colorectal cancer, targeting angio-
genesis was thought to be a good treatment approach.
Targeting Angiogenesis in Colon  
Cancer
A  variety  of  strategies  have  been  investigated 
to  exploit  the  role  of  the  VEGF  pathway  in 
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Figure 1. Schematic illustration of the family of veGF receptors, ligands and their functions. There are six veGF ligands, veGF-A, veGF-B, veGF-C, veGF-D, 
VEGF-E, and PIGF and three main VEGF receptors, VEGFR-1, VEGFR-2, and VEGFR-3. Each VEGF ligand has specific affinity to different receptors as 
illustrated. Binding of ligands to the extramembrane domain of the receptors trigger dimerization of the receptor, autophosphorylation of the tyrosine kinase 
domain of the receptor, and initiate multiple downstream signal transduction pathways that result in endothelial cell proliferation, migration, survival, and more. 
(The figure is modified from Salmon,8 Cross,9 and Kerbel10).
Abbreviations: veGF, vascular endothelial growth factor; PIGF, placenta growth factors; FAK, focal adhesion kinase; PI3K, phosphatidylinositol 3-kinase.wang and Lockhart
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colorectal cancer. To date, the most successful agent 
has  been  bevaci-zumab,  a  humanized  monoclonal 
antibody that binds to VEGF-A and prevents interaction 
between  VEGF-A  and  VEGFR.  Another  targeting 
strategy  is  to  use  small  molecular  tyrosine  kinase 
inhibitors, such as sunitinib and sorafenib, which bind 
to the intracellular kinase domain of the receptor and 
interfere with its tyrosine kinase activities essential 
for  downstream  signaling.  Additional  monoclonal 
antibodies  against  the  extracellular  domains  of 
VEGFRs are also under development. Furthermore, 
agents against VEGF messenger RNAs, endogenous 
antiangiogenic factors angiostatin and endostatin, and 
endothelial tubulin disruption agents, as well as others 
are all under active investigation at various stages of 
clinical development.8
Bevacizumab  is  currently  the  only  agent 
approved by the US Food and Drug Administration 
(FDA)  specifically  targeting  the  VEGF  pathway 
for  the  treatment  of  colorectal  cancer.  It  improves 
progression-free survival and overall survival when 
given to patients with metastatic colorectal cancer in 
combination with cytotoxic chemotherapy.4 It is usually 
administrated  in  combination  with  the  FOLFOX 
(5-fluorouracil,  leucovorin,  and  oxaliplatin)  or 
FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) 
chemotherapy regimens, and is therefore approved for 
use in this setting.4,22,23 Agents inhibiting angiogenesis 
provide  different  mechanisms  and  toxicity  profiles 
from traditional chemotherapy; hence, the approach of 
combining angiogenesis inhibitors with chemotherapy 
to achieve better disease control without an increase 
in toxicity has been widely adopted. However, even 
with  bevacizumab,  the  median  progression-free 
survival  of  metastatic  colorectal  cancer  patients 
remains  less  than  one  year,  with  median  overall 
survival being approximately 2 years.4,24 Therefore, 
improving the response rate, response durability, and 
survival with new targeted agents remains an area 
of  active  investigation.  Aflibercept  (Sanofi-aventis 
and Regeneron Pharmaceuticals Inc) is a new agent 
targeting the VEGF pathway. Aflibercept has recently 
been  shown  to  be  well  tolerated  and  effective  in 
treating  patients  with  metastatic  colorectal  cancer 
when  combined  with  cytotoxic  chemotherapy.25  In 
the second part of this review, we will summarize 
the use of aflibercept in the treatment of metastatic 
colorectal cancer.
Small molecule tyrosine kinase inhibitors block 
the tyrosine kinase activities of VEGF receptors, thus 
preventing phosphorylation of signaling proteins in 
the  downstream  pathway.  Multiple  tyrosine  kinase 
inhibitors have been developed, among which suni-
tinib and sorafenib have been approved by the FDA 
for the treatment of metastatic renal and hepatic can-
cer.26–28  More  tyrosine  kinase  inhibitors  are  under 
active  investigation.  No  tyrosine  kinase  inhibitors 
have yet been approved for the treatment of colorectal 
cancer. In large Phase III trials, vatalanib, a tyrosine 
kinase inhibitor for all three VEGFRs, was compared 
with placebo when combined with FOLFOX in both 
first-line and second-line settings (CONFIRM 1 and 
CONFIRM 2, respectively). Surprisingly, the primary 
endpoints were not achieved in either trial (progres-
sion-free survival in CONFIRM 1 and overall sur-
vival in CONFIRM 2).29,30 Ongoing Phase I or II trials 
are investigating the efficacy of other tyrosine kinase 
inhibitors in colorectal cancer. It is worth noting that 
the majority of tyrosine kinase inhibitors target mul-
tiple different receptor tyrosine kinases given their 
structural similarity, leading to desired and undesired 
“off-target” effects.
Given that antibodies against VEGF ligands have 
been  proven  to  be  effective  in  treating  metastatic 
colorectal  cancer,  antibodies  against  VEGF  recep-
tors are also of great interest. Preclinical studies have 
demonstrated the efficacy of a VEGFR-2 antibody in 
inhibiting  tumor  growth,  angiogenesis,  metastasis, 
and tumor cell survival.31,32 To date, only one Phase I 
trial has been published investigating a fully human-
ized monoclonal antibody against VEGFR-2, ramuci-
rumab (IMC-1121B).33 It was well tolerated without 
significant toxicity in this small study. Phase II and 
III studies are ongoing to incorporate ramucirumab in 
the treatment of a variety of malignancies, including 
colorectal, liver, kidney, prostate, ovarian, malignant 
melanoma, and nonsmall cell lung cancer.34
Combining  angiogenesis-targeting  agents  with 
cytotoxic chemotherapy not only provides the advan-
tage of nonoverlapping toxicity and therefore good 
tolerance, but also serves to enhance efficacy. The 
mechanism of increased efficacy with combination 
therapy has been explored. Experimental models have 
demonstrated  that  tumors  have  disorganized  vas-
culature and lymphatics, leading to increased inter-
stitial fluid pressure and poor delivery of cytotoxic Aflibercept in metastatic colorectal cancer
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  chemotherapy  and  hypoxia,  thereby  providing 
resistance to chemotherapy and radiation. Jain et al, 
as well as other investigators, have shown that with 
anti-VEGF agents, the disorganized and inefficient 
vasculature can be corrected.35 Therefore, the deliv-
ery of chemotherapy and even radiation is improved, 
as demonstrated by Willett et al.35,36
Table 1 contains a list of VEGF targeted agents 
currently approved by the FDA. Aflibercept is also 
included  for  comparison,  although  it  has  not  been 
approved  by  the  FDA.  Their  approved  treatment 
indications and their usage in colorectal cancer are 
highlighted.
Clinical Trials with Aflibercept  
in Colorectal Cancer
Pharmacodynamics and pharmacokinetics
Aflibercept  (VEGF  trap)  is  a  fully  humanized 
recombinant  fusion  protein  composed  of  the 
extracellular  domain  2  from  VEGFR-1,  the  extracellular 
domain 3 from VEGFR-2, and the constant region of 
human immunoglobulin G1. It functions as a decoy 
VEGF  receptor,  binds  VEGF-A,  VEGF-B,  and 
placental growth factors 1 and 2 with high affinity, 
prevents their binding to native VEGF receptors, and 
therefore inhibits angiogenesis. In vitro, aflibercept 
is able to block VEGF-induced phosphorylation of 
VEGFR-2  and  VEGF-mediated  cell  proliferation 
completely.37 In vivo, VEGF trap significantly inhibits 
the growth of various tumors (including melanoma, 
rhabdomyosarcoma,  glioma,  and  neuroblastoma), 
and  tumor-associated  angiogenesis  in  mouse 
xenograft  models.38  In  neuroblastoma  cells,  it  was 
found that one of the main mechanisms of resistance 
to angiogenesis inhibitors is the co-option of blood 
vessels  from  the  host.38  High-dose  aflibercept  can 
overcome this resistance by causing regression of the 
co-opted host vessels and providing near-complete 
blockage  of  angiogenesis.  This  same  effect  is  not 
seen with bevacizumab or low-dose aflibercept. In 
preclinical assessments, aflibercept results in stronger 
angiogenesis inhibition than does bevacizumab for 
several reasons, ie, at least 100–1000 times higher 
affinity  to  the  circulating  VEGFs,  longer  half-life, 
and  added  affinity  to  the  placental  growth  factors   
1 and 2.38 Table 2 is a summary of aflibercept trials 
in patients with metastatic colorectal cancer. Some of 
these pivotal trials are discussed in detail.
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Table 2. Summary of clinical trials of aflibercept in metastatic colorectal cancer.
Trial n Dose of aflibercept Setting Combination  
chemotherapy
Result
Phase I39 7/47a 3, 4, 7 mg/kg Iv  
every 2 weeks
Single agent,  
dose escalation
None 4 PR but none in  
colorectal cancer
Phase I59 23/38b 2–6 mg/kg Iv  
every 2 weeks
Second-line,  
with chemo
I-Lv5FU2 7 PR (4 colon) 19 SD
Phase II42 51 4 mg/kg Iv  
every 2 weeks
Second-line,  
Single agent
None DCR 29%–30% 
PFS 2–3.4 mo
Phase II 
(AFFIRM)46
230c 4 mg/kg Iv  
every 2 weeks
First-line, 
with chemo
Modified  
FOLFOX6
Pending
Phase III 
(veLOUR)25
614/1226d 4 mg/kg Iv  
every 2 weeks
Second-line,  
with chemo
FOLFIRI PFS 6.9 mo 
OS 13.5 mo 
RR 19.8% 
Superior to placebo
Notes: a7 out of 47 patients received aflibercept had colorectal cancer; b23 out of 38 patients received aflibercept had colorectal cancer; ctotal number of 
patients in the trial, number of patients received aflibercept is unknown; d614 out of 1226 patients received aflibercept, other patients received placebo.
Abbreviations: IV, intravenous; PR, partial response; Chemo, chemotherapy; I-LV5FU2, irinotecan, leucovorin, and 5-fluorouracil (fixed standard dose); 
SD, stable disease; DCR, disease control rate (any response plus stable disease); Modified FOLFOX6, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI; 
5-fluorouracil, leucovorin, and irinotecan.
Phase I Clinical Studies
The first Phase I study, published by Lockhart et al, 
aimed  to  evaluate  the  safety,  pharmacokinetics,  and 
pharmacodynamics  of  intravenously  administered 
  single-agent aflibercept.39 Forty-seven patients with a 
variety of refractory solid tumors received aflibercept on 
study, of whom seven had colorectal cancer. Aflibercept 
was given in escalating doses from 0.3 to 7.0 mg/kg 
intravenously every 2 weeks. The half-life of aflibercept 
was observed to increase with dose escalation, ranging 
from 1.7 (0.3 mg/kg cohort) to 7.4 days (5.0 mg/kg 
cohort). Steady-state was not reached until at least 3 
weeks after the first dose of aflibercept. No antibodies 
against  aflibercept  were  detected.  Bound  aflibercept 
levels (aflibercept bound to circulating VEGF) reached 
a maximum at the dose of 2 mg/kg, and free aflibercept 
levels  were  consistently  exceeding  the  bound  levels 
beyond this dose, indicating saturation and blockage of 
VEGF ligands at doses $2 mg/kg. Additionally, higher 
doses resulted in increasing toxicity. Therefore, 4 mg/kg   
was determined to be the recommended dose for the 
Phase II and III combination studies.
In  this  Phase  I  study,  antitumor  responses  were 
observed in four patients.39 One patient with malignant 
thymoma and two patients with ovarian cancer had 
confirmed partial responses by RECIST criteria. One 
other patient with ovarian cancer had an unconfirmed 
partial response. Additionally, two patients with renal 
cell cancer had stable disease for more than one year.
Aflibercept was well tolerated. The dose-limiting 
toxicities  were  proteinuria  and  rectal  ulceration 
observed at the dose of 7 mg/kg.39 The most common 
adverse effects were fatigue (63.8%), nausea (36.2%), 
and vomiting (27.7%), while the most common tox-
icities  included  dysphonia  (46.8%),  hypertension 
(38.3%),  and  proteinuria  (10.6%).  Adverse  events 
were generally mild and reversible upon aflibercept 
discontinuation or initiation of appropriate supportive 
care, such as antihypertensives. The median onset of 
hypertension was 3.5 days and that of proteinuria was 
15 days.
Multiple other Phase I trials have demonstrated 
the  safety  of  combining  aflibercept  with  cytotoxic 
chemotherapy typically used for metastatic colorectal 
cancer, such as FOLFOX and ILV5FU2 (5-fluoroura-
cil, leucovorin, and irinotecan). Other chemotherapies 
such as docetaxel, gemcitabine, pemetrexed, cispla-
tin, and temozolomide have also been combined with 
aflibercept with good safety and tolerability.6,40,41
Phase II Clinical Studies
A multicenter, open-label, Phase II trial investigated 
aflibercept  in  patients  with  previously  treated 
metastatic  colorectal  cancer.42  The  preliminary 
results  from  this  study  were  reported  at  the 
2008  American  Society  of  Clinical  Oncology 
annual  meeting.  Fifty-one  patients  were  enrolled 
in two cohorts, ie, bevacizumab-naïve (n = 24) or Aflibercept in metastatic colorectal cancer
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bevacizumab-treated (n = 27). Single-agent aflibercept 
was  given  at  the  dose  of  4  mg/kg  intravenously 
every 2 weeks. The primary endpoints were disease 
response rate and 4-month progression-free survival. 
The disease control rate (including partial response 
and stable disease) was 29% in bevacizumab-naïve 
and  30%  in  bevacizumab-treated  cohorts,  with 
median progression-free survival of 2.0 months and 
3.4 months, respectively. The most common adverse 
reactions were fatigue (78%), hypertension (55%), 
proteinuria (49%), and headache (43%). The authors 
concluded that aflibercept was well tolerated and had 
modest activity against refractory/relapsed metastatic 
colorectal cancer as a single agent, regardless of prior 
therapy with bevacizumab.
Many  other  ongoing  Phase  II  trials  have  found 
aflibercept to be safe and well tolerated in a variety 
of solid tumors, including nonsmall cell lung can-
cer, ovarian cancer, gynecologic soft tissue sarcoma, 
transitional cell carcinoma, melanoma, and malignant 
glioblastoma.43
Phase III Clinical Studies
VELOUR  is  a  multicenter,  randomized,  placebo-
  controlled Phase III trial, with the goal of comparing the 
efficacy of aflibercept versus placebo in combination 
with the FOLFIRI regimen as a second-line treatment 
for patients with metastatic colorectal cancer previously 
treated  with  oxaliplatin.25  Enrolled  patients  included 
patients with metastatic colorectal cancer, Eastern Coop-
erative Oncology Group performance status 0–2, and 
adequate organ function after failing one oxaliplatin-
based therapy. From November 2007 to March 2010, 
1226 patients were enrolled, with a median age of 61 
years; 58.6% were male, 97.9% of patients had a good 
performance status (0–1), and 30.4% of patients had 
received  bevacizumab  previously.  Patients  were  ran-
domized to receive FOLFIRI and aflibercept at 4 mg/kg 
intravenously every 2 weeks (n = 614) versus FOLFIRI 
and placebo (n = 612), with stratification by performance 
status and prior bevacizumab. The primary endpoint was 
overall survival, while the secondary endpoints included 
progression-free survival, overall response rate, safety, 
and aflibercept pharmacokinetics and immunogenicity.
The  final  data  collection  for  primary  out-
comes was recently completed and presented at the 
2011   meeting of the European Society for Medical 
  Oncology World Congress on Gastrointestinal   Cancer. 
After  a  median  follow-up  of  22.28  months,  the 
aflibercept  group  showed  superior  median  overall 
survival (13.50 months versus 12.06 months,   hazards 
ratio 0.817, P = 0.0032) and progression-free sur-
vival  (6.90  months  versus  4.67  months,  hazards 
ratio 0.758, P = 0.00007) compared with the placebo 
group. The overall response rate in the aflibercept 
group was 19.8% compared with 11.1% in the pla-
cebo group (P = 0.0001). Grade 3 or 4 adverse events 
associated with aflibercept included diarrhea, fatigue, 
stomatitis, infections, hypertension, abdominal pain, 
neutropenia, and proteinuria (Fig. 2). Adverse events 
led to treatment discontinuation in 26.6% of patients 
in the aflibercept group, compared with 12.1% in the 
placebo group. The authors concluded that afliber-
cept in combination with FOLFIRI improved over-
all survival and progression-free survival in patients 
with metastatic colorectal cancer previously treated 
with oxaliplatin. While improvement in the primary 
outcomes  was  significant,  it  is  unknown  whether 
the addition of aflibercept translated into improve-
ment in other important clinical outcomes, such as 
  quality of life, considering the high rate of treatment 
discontinuation. Some toxicities potentially contrib-
uting to the discontinuation rate include doubling of 
the rate of diarrhea (2.5 times), febrile neutropenia 
(2.0 times), stomatitis (2.7 times), and infections (2.0 
times). In addition, there were several-fold increases 
in hypertension (13 times) and proteinuria (6.5 times) 
in patients receiving aflibercept (Fig. 2). Given its 
potential use in the palliative setting, significant side 
effects and potential harm to the patients’ quality of 
life are crucial factors to be considered, in addition 
to response rate and survivorship. More data in this 
regard are expected to be available for review upon 
final study publication.
Common Toxicity of Aflibercept
Aflibercept  demonstrated  toxicity  similar  to  other 
agents targeting the VEGF pathway, such as beva-
cizumab. The most common adverse events in clini-
cal trials included hypertension, proteinuria, fatigue, 
and  diarrhea  (Fig.  2).  Table  3  compares  the  main 
side effects observed in the Phase III VELOUR trial 
(aflibercept combined with FOLFIRI) with those in 
the Phase IV AVIRI study (bevacizumab in combi-
nation with FOLFIRI).22,23 This comparison could be 
informative, although a cross-trial comparison carried wang and Lockhart
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inherent problems and needed to be interpreted with 
great  caution.  For  example,  the  patient  population 
differed  between  the  two  trials; VELOUR  investi-
gated the regimen as a second-line treatment, while 
in the AVIRI study, bevacizumab plus FOLFIRI were 
used in the first-line setting. As shown in Table 3, the 
most noticeable difference was that aflibercept trials 
revealed a numerically higher risk of hypertension and 
proteinuria of any grade and grade 3/4. Proteinuria of 
any grade was reported in 62% of patients receiving 
aflibercept, while approximately 8% had proteinuria 
of more than grade three. In the AVIRI study, bevaci-
zumab was associated with an incidence of proteinu-
ria of any grade and proteinuria $grade 3 of 3.3% and 
1.9%, respectively. Any grade of hypertension was 
reported in 41% of patients on the aflibercept arm, 
compared with close to 20% with $grade 3. In patients 
receiving  bevacizumab,  28%  developed  hyperten-
sion of any degree, while 5%–10% developed more 
severe hypertension ($grade 3). In Phase III trials of 
other small molecule tyrosine kinase inhibitors, such 
as sunitinib and sorafenib, which shared many of the 
toxicities of VEGF antagonists, the rates of hyperten-
sion were found to be closer to that of bevacizumab. 
Any grade and grade 3/4 of hypertension were found 
in 24% and 8% of patients taking   sunitinib, whereas 
these  were  observed  in  17%  and  4%  of  patients 
on  sorafenib,  respectively.26,27  The  reason  for  this 
increased toxicity in the aflibercept group was unclear, 
but the enhanced affinity of aflibercept for VEGF-A 
and stronger inhibition of the VEGF pathway might 
play a role. Additionally, it is worth noting that in the 
VELOUR trial, the rate of proteinuria found in the 
placebo arm was higher than expected, ie, 40.7% with 
any grade and 1% with grade 3/4. Gastrointestinal per-
forations, fistula, and wound healing complications 
were rare events and occurred in less than 1% of the 
patients.
Adverse  events,  such  as  hypertension,  were 
  generally  manageable  with  medications.  Currently, 
there  are  no  standard  guidelines  on  management 
for VEGF inhibitor-associated hypertension. In the 
initial pivotal trial investigating the combination of 
bevacizumab and chemotherapy in the treatment of 
metastatic colorectal cancer, all hypertensive episodes 
were  manageable  with  standard  antihypertensives 
such  as  angiotensin-converting  enzyme  inhibitors, 
calcium channel blockers, and diuretics.4 In recent 
years, advantages of angiotensin-converting enzyme 
inhibitors  and  angiotensin  II  receptor  blockers  in 
this population have been identified, including a low 
interaction  potential  with  antiangiogenesis  agents, 
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Figure 2. Grade 3/4 adverse events with .5% differe nce in incidence between aflibercept and placebo arms in the VELOUR trial.
Notes: *FN: Febrile neutropenia. Difference in incidence of febrile neutropenia did not exceed 5% (3.9%), but was included due to its clinical significance.Aflibercept in metastatic colorectal cancer
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the benefit of addressing treatment-induced proteinu-
ria concurrently, and prevention of the expression of 
plasminogen  activator  inhibitor-1.44,45  Plasminogen 
activator inhibitor-1 was often found to be stimulated 
by  antiangiogenesis  agents,  resulting  in  resistance 
of fibrinolysis and a higher risk of thrombosis.44,45 
Furthermore, in multiple cancer cell lines and animal 
models,  angiotensin-converting  enzyme  inhibitors 
and angiotensin II receptor blockers were found to 
delay tumor cell growth, which was thought to be due 
to the effects of angiotensin II inhibition.45 Therefore, 
some  researchers  advocated  angiotensin-converting 
enzyme inhibitors or angiotensin II receptor blockers 
to be among the first-line therapies for hypertension 
associated with angiogenesis blockers.44,45
Current Place of Aflibercept in  
Treatment of Metastatic Colorectal  
Cancer
Given the preliminary positive results of the Phase 
III  VELOUR  trial,  Sanofi-Aventis  and  Regeneron 
Pharmaceuticals Inc, are preparing to submit regula-
tory applications for marketing approval to the US 
FDA and European Medicines Agency later this year. 
If  successful,  aflibercept  will  become  the  second 
VEGF pathway targeted agent approved for the treat-
ment of metastatic colorectal cancer. It is anticipated 
that  this  agent  would  be  administered  along  with 
FOLFIRI  chemotherapy  in  patients  whose  tumors 
have progressed despite first-line therapy.
Future Directions
Multiple Phase I, II, and III trials are ongoing to 
investigate  the  effects  of  aflibercept  alone  or  in 
combination  with  chemotherapy  to  treat  a  variety 
of malignancies. The AFFIRM trial is an   ongoing 
Phase  II  study  investigating  the  combination  of 
aflibercept with FOLFOX as the first-line   treatment 
for  metastatic  colorectal  cancer.46  The  trial  has 
completed  accrual  and  its  preliminary  results  are 
expected  in  late  2011.  Given  that  bevacizumab 
showed a 5-month improvement in overall survival 
when combined with irinotecan, bolus fluorouracil, 
and leucovorin in an untreated population, it is of 
great interest how aflibercept would perform in this 
similar  clinical  setting.4  When  more  new  agents 
targeting  the VEGF  pathway  become  available,  it 
would be prudent to compare the efficacy of these new 
agents with existing therapies, such as bevacizumab. 
The  preliminary  results  of  the VELOUR  trial  are 
comparable with those of E3200, the Phase III trial 
comparing FOLFOX with or without   bevacizumab as 
second-line therapy in patients who have progressed 
on   irinotecan-based therapy.47 The optimal sequence 
of  these  biological  agents,  possibility  of  cross-
resistance, and utility of the continuation of VEGF 
inhibition after progression are also important clinical 
questions that need to be answered.
Another area to be explored is the combination of 
VEGF and EGFR (endothelial growth factor receptor) 
blockade. Preclinical data and Phase II BOND-2 trial 
provided encouraging results on the combination of 
bevacizumab and cetuximab (an endothelial growth 
factor receptor inhibitor) with irinotecan in patients with 
metastatic colorectal cancer refractory to   irinotecan.48 
However, large Phase III trials disappointingly showed 
increased  toxicity  with  shortened  progression-free 
survival when panitumumab or cetuximab was added 
to bevacizumab with chemotherapy.49,50 The reasons 
of these failed Phase III trials are unclear, and it is also 
unknown that if aflibercept can perform better in a 
similar situation.
Table 3. Comparison of grade 3 or 4 adverse events in 
phase III trials with aflibercept vs. bevacizumab.24,25
Adverse events Aflibercept +  
FOLFIRI (%)
Bevacizumab +   
FOLFIRI (%)
Neutropenia 36.7 29
Febrile neutropenia 5.7 6
Diarrhea 19.3 12
Fatigue 16.9 10
Hypertension  
(any grade)
41.4 28
Hypertension  
(grade 3/4)
19.3 5*
venous thrombosis 7.9 18
Arterial thrombosis 1.8 4
Hemorrhage  
(grade 3/4)
2.9 4.0
Proteinuria  
(any grade)
62.2 3.3
Proteinuria  
(grade 3/4)
7.9 1.9
Gastrointestinal  
perforation
0.5 2
Fistula 0.3 1
wound healing issues 0.3 ,1
Note: *Other large phase III trials of similar regimen have reported a rate 
of grade 3 or 4 hypertension to be higher than 10%.4,22wang and Lockhart
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The efficacy of anti-VEGF in the adjuvant setting 
is of interest to researchers due to the good perfor-
mance of bevacizumab in metastatic colorectal cancer. 
However, bevacizumab failed to show benefits when 
combined with cytotoxic chemotherapy as adjuvant 
therapy in two large, randomized, Phase III trials.51,52 
Considering that aflibercept is a much stronger VEGF 
inhibitor than bevacizumab, one may speculate on its 
possible efficacy in the adjuvant setting to treat these 
microscopic metastases.
Other  active  Phase  III  studies  on  aflibercept 
include  the  VENICE  trial,  evaluating  aflibercept 
versus placebo combined with docetaxel and pred-
nisone in treating patients with metastatic androgen 
independent prostate cancer, and the VITAL trial, 
evaluating  aflibercept  versus  placebo  in  combi-
nation  with  docetaxel  as  a  second-line  treatment 
for  patients  with  metastatic  nonsmall  cell  lung 
cancer.53,54 Table  4  is  a  summary  of  the  ongoing 
Phase III trials incorporating aflibercept. Although 
the preliminary results from the VITAL trial indi-
cated that the addition of aflibercept to docetaxel 
failed to improve overall survival, its progression-
free survival and overall response rate were   superior 
to placebo. Final results remain to be seen after their 
data are published.54
Given the significantly increased toxicity associ-
ated with aflibercept and other VEGF inhibitors, it is 
important to identify patients who would benefit most 
from  VEGF  inhibitors  and  avoid  treatment-related 
toxicities in patients who will not benefit. Circulating 
biomarkers, such as VEGF and VEGFR2, have been 
investigated, but have not consistently demonstrated 
prognostic value.55 There is ongoing research to iden-
tify more reliable factors to assist in these important 
clinical decisions.
Conclusion
Aflibercept is a new agent targeting the VEGF path-
way in the treatment of solid tumors. The VELOUR 
trial showed the efficacy of aflibercept in improving 
progression-free  survival  and  overall  survival  when 
combined with FOLFIRI as a second-line treatment for 
metastatic colorectal cancer. Aflibercept is also asso-
ciated  with  increased  toxicities,  such  as  proteinuria 
and hypertension. Ongoing Phase II and Phase III tri-
als will determine further the role of aflibercept in the 
treatment of colorectal cancer and other solid tumors.
Table 4. Summary of phase III trials of aflibercept.
Trial n Targeted disease Setting Regimen Endpoints Status
veLOUR25 1226 Metastatic  
colorectal  
cancer
Second-line FOLFIRI  
± aflibercept
OS* 
PFS 
ORR 
Safety 
Immunogenicity
Completed, awaiting   
publication.  
(superior OS  
and PFS)
vITAL54 900+ Locally advanced  
or metastatic  
non-small- 
cell lung cancer
Second-line Docetaxel  
± aflibercept
OS* 
PFS 
ORR 
Symptoms
Completed, awaiting   
publication. (OS no  
difference, superior  
PFS and ORR)
veNICe53 1200+ Metastatic androgen  
independent prostate  
cancer
First-line chemo  
after failing  
androgen
Docetaxel/ 
Prednisone  
± aflibercept
OS* 
PSA 
Pain 
Skeletal related  
events
Ongoing, results  
are expected in  
June 2012
vANILLA60 546 Metastatic  
pancreatic  
adenocarcinoma
First-line Gemcitabine  
± aflibercept
OS* 
PFS 
ORR 
Safety 
Clinical benefit  
based on symptoms 
Immunogenicity
early termination  
in 2009 (failure to 
achieve primary  
outcomes)
Notes: +estimated enrollment; *primary end point(s), the rest are secondary endpoints.
Abbreviations: FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; OS, overall survival; PFS, progression free survival; ORR, overall response rate; PSA, 
prostate specific antigen.Aflibercept in metastatic colorectal cancer
Clinical Medicine Insights: Oncology 2012:6  29
Disclosures
Author(s) have provided signed confirmations to the 
publisher of their compliance with all applicable legal 
and ethical obligations in respect to declaration of con-
flicts of interest, funding, authorship and contributor-
ship,  and  compliance  with  ethical  requirements  in 
respect to treatment of human and animal test subjects. 
If  this  article  contains  identifiable  human  subject(s) 
author(s) were required to supply signed patient consent 
prior to publication. Author(s) have confirmed that the 
published article is unique and not under consideration 
nor published by any other publication and that they 
have consent to reproduce any copyrighted material. 
The peer reviewers declared no conflicts of interest.
References
  1.  Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics. CA Cancer J Clin. 
2011;61:212–36.
  2.  Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer 
statistics. CA Cancer J Clin. 2011;61:69–90.
  3.  American Cancer Society. Cancer Facts and Figures 2011. Available from: 
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ 
documents/document/acspc-029771.pdf. Accessed November 18, 2011.
  4.  Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinote-
can, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J 
Med. 2004;350:2335–42.
  5.  Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 
1971;285:1182–6.
  6.  Chu E. An update on the current and emerging targeted agents in metastatic 
  colorectal cancer. Clin Colorectal Cancer. July 11, 2011. [Epub ahead of 
print.]
  7.  Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. 
Oncogene. 2003;22:6549–56.
  8.  Salmon JS, Lockhart AC, Berlin J. Anti-angiogenic treatment of gastroin-
testinal malignancies. Cancer Invest. 2005;23:712–26.
  9.  Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor 
  signal transduction. Trends Biochem Sci. 2003;28:488–94.
  10.  Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–49.
  11.  Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in 
the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19: 
5598–605.
  12.  Fong  GH,  Rossant  J,  Gertsenstein  M,  Breitman  ML.  Role  of  the  Flt-1 
  receptor tyrosine kinase in regulating the assembly of vascular endothelium. 
Nature. 995;376:66–70.
  13.  Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the 
tyrosine kinase domain is sufficient for normal development and angiogen-
esis in mice. Proc Natl Acad Sci U S A. 1998;95:9349–54.
  14.  Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/
vascular  endothelial  growth  factor  (VEGF)  peceptor-1  down-  modulates 
VPF/VEGF  receptor-2-mediated  endothelial  cell  proliferation,  but  not 
migration,  through  phosphatidylinositol  3-kinase-dependent  pathways.   
J Biol Chem. 2001;276:26969–79.
  15.  Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor   pathway 
in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.
  16.  Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation 
and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62–6.
  17.  Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital 
hereditary  lymphedema  caused  by  a  mutation  that  inactivates VEGFR3 
tyrosine kinase. Am J Hum Genet. 2000;67:295–301.
  18.  Achen MG, Williams RA, Minekus MP, et al. Localization of vascular 
endothelial  growth  factor-D  in  malignant  melanoma  suggests  a  role  in 
tumour angiogenesis. J Pathol. 2001;193:147–54.
  19.  Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of 
vascular endothelial growth factor and its receptor, KDR, correlates with 
vascularity, metastasis, and proliferation of human colon cancer. Cancer 
Res. 1995;55:3964–8.
  20.  Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of 
vascular endothelial growth factor as prognostic factors in node-negative 
colon cancer. Arch Surg. 1997;132:541–6.
  21.  Cascinu  S,  Staccioli  MP,  Gasparini  G,  et  al.  Expression  of  vascular 
endothelial growth factor can predict event-free survival in stage II colon 
cancer. Clin Cancer Res. 2000;6:2803–7.
  22.  Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of 
irinotecan  plus  infusional,  bolus,  or  oral  fluoropyrimidines  in  first-line 
treatment of metastatic colorectal cancer: results from the BICC-C Study.   
J Clin Oncol. 2007;25:4779–86.
  23.  Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination 
with oxaliplatin-based chemotherapy as first-line therapy in metastatic 
colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26: 
2013–9.
  24.  Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab 
in  combination  with  infusional  fluorouracil,  leucovorin  and  irinotecan   
(FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009;77: 
113–9.
  25.  Van  Cutsem  E,  Tabernero  J,  Lakomy  R.  Intravenous  aflibercept  versus 
  placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line 
treatment of metastatic colorectal cancer (MCRC): results of a multinational 
Phase III trial (EFC10262-VELOUR). Ann Oncol. 2011:22.
  26.  Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in 
metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.
  27.  Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell 
renal-cell carcinoma. N Engl J Med. 2007;356:125–34.
  28.  Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular 
carcinoma. N Engl J Med. 2008;359:378–90.
  29.  Hecht  JR,  Trarbach  T,  Jaeger  E. A  randomized,  double-blind,  placebo-
  controlled, phase III study in patients (Pts) with metastatic adenocarcinoma 
of the colon or rectum receiving first-line chemotherapy with oxaliplatin/ 
5-  fluorouracil/leucovorin  and  PTK787/ZK  222584  or  placebo  (CON-
FIRM-1). J Clin Oncol. 2005;23 Suppl 2:Abstr LBA3.
  30.  Kohne C, Bajetta E, Lin E. Final results of CONFIRM 2: A multinational, 
randomized, double-blind, phase III study in 2nd line patients (pts) with 
metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 
222584 (PTK/ZK) or placebo. J Clin Oncol. 2007;25 Suppl 18S:4033.
  31.  Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth   factor recep-
tor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis 
and growth of several mouse and human tumors. Cancer Res. 1999;59: 
5209–18.
  32.  Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel 
attack on angiogenesis. Future Oncol. 2010;6:1085–94.
  33.  Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and   biologic 
study  of  ramucirumab  (IMC-1121B),  a  fully  human  immunoglobulin 
G1 monoclonal antibody targeting the vascular endothelial growth factor 
receptor-2. J Clin Oncol. 2010;28:780–7.
  34.  Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF 
treatment with large molecules. Nat Rev Clin Oncol. 2009;6:507–18.
  35.  Jain  RK.  Normalizing  tumor  vasculature  with  anti-angiogenic  therapy:   
a new paradigm for combination therapy. Nat Med. 2001;7:987–9.
  36.  Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF- 
specific antibody bevacizumab has antivascular effects in human rectal cancer.   
Nat Med. 2004;10:145–7.
  37.  Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker 
with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11393–8.
  38.  Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression 
of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A. 
2002;99:11399–404.Publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
wang and Lockhart
30  Clinical Medicine Insights: Oncology 2012:6
  39.  Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous 
vascular endothelial growth factor trap, aflibercept, in patients with advanced 
solid tumors. J Clin Oncol. 2010;28:207–14.
  40.  Townsley CA, Siu LL, Pedro-Salcedo MS. A Phase I study of aflibercept, 
pemetrexed, and cisplatin in patients with advanced solid tumors. J Clin 
Oncol. 2010;28 Suppl 15:Abstr 2536.
  41.  De Groot JF, Cloughesy T, Lieberman FS. Phase I study of aflibercept and 
temozolomide in newly diagnosed, high-grade glioma. J Clin Oncol. 2011; 
Suppl 29:Abstr 2043.
  42.  Tang P, Cohen SJ, Bjarnason GA. Phase II trial of aflibercept (VEGF Trap) 
in previously treated patients with metastatic colorectal cancer (MCRC):   
a PMH phase II consortium trial. J Clin Oncol. 2008;Suppl 26:Abstr 4027.
  43.  Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications 
of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73: 
449–56.
  44.  Dincer  M,  Altundag  K.  Angiotensin-converting  enzyme  inhibitors  for 
  bevacizumab-induced hypertension. Ann Pharmacother. 2006;40:2278–9.
  45.  Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in 
angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807–15.
  46.  US National Institutes of Health. Study of Aflibercept and Modified FOL-
FOX6 As First-line treatment in patients with metastatic   colorectal cancer 
(AFFIRM). Available from: http://clinicaltrials.gov/ct2/show/NCT00851084. 
Accessed September 21, 2011.
  47.  Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination 
with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously 
treated metastatic colorectal cancer: results from the Eastern Cooperative 
Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.
  48.  Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of   cetuximab, 
bevacizumab, and irinotecan compared with cetuximab and bevacizumab 
alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin 
Oncol. 2007;25:4557–61.
  49.  Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab 
in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.
  50.  Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemo-
therapy, bevacizumab, and panitumumab compared with chemotherapy and 
bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27: 
672–80.
  51.  Allegra  CJ,  Yothers  G,  O’Connell  MJ,  et  al.  Phase  III  trial  assessing 
  bevacizumab in stages II and III carcinoma of the colon: results of NSABP 
protocol C-08. J Clin Oncol. 2011;29:11–6.
  52.  Investor update. Available from: http://www.roche.com/investors/ir_update/
inv-update-2010-09-18b.html. Accessed September 28, 2011.
  53.  US  National  Institutes  of  Health.  Aflibercept  in  Combination  With 
  Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE). 
Available from: http://clinicaltrials.gov/ct2/show/NCT00519285. Accessed 
  September 21, 2011.
  54.  US National Institutes of Health. A study of aflibercept versus placebo in 
patients with second-line docetaxel for locally advanced or metastatic non-
small-cell lung cancer (VITAL). Available from: http://clinicaltrials.gov/
ct2/show/NCT00532155. Accessed September 21, 2011.
  55.  Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role 
in the development of VEGF inhibitors. Br J Cancer. 2010;102:8–18.
  56.  Hecht JR, Yoshino T, Mitchell EP, et al. A randomized, phase IIb study of 
sunitinib  plus  5-fluorouracil,  leucovorin,  and  oxaliplatin  (mFOLFOX6) 
versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic 
colorectal cancer (mCRC): Interim results. J Clin Oncol. 2010;28 Suppl 15: 
Abstr 3532.
  57.  Samson B, Latreille J, Nguyen NT, Sperlich C, Berbiche D, Tournigand C. 
SUNCAP, a phase II study with sunitinib and capecitabine in patients with 
metastatic colorectal cancer (MCRC) refractory to previous treatment with 
5FU/irinotecan/oxaliplatin. J Clin Oncol. 2011;29 Suppl 4:Abstr 545.
  58.  Ychou M, Bouche O, Thézenas S, et al. Final results of a multicenter phase II   
trial assessing sorafenib (S) in combination with irinotecan (i) as second- or 
later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) 
with KRAS-mutated tumors (mt; NEXIRI). J Clin Oncol. 2011;29 Suppl: 
Abstr e14002.
  59.  Rixe O, Verslype C, Khayat D, et al. A phase I dose escalation (DE) and 
pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus 
irinotecan,  5-fluorouracil,  and  leucovorin  (I-LV5FU2)  in  patients  with 
advanced solid tumors (STs). J Clin Oncol. 2008;26 Suppl:Abstr 3557.
  60.  US National Institutes of Health. Aflibercept compared to placebo in term of 
eficacyin patients treatedwith gemcitabine for metastaticpancreatic   cancer 
(VANILLA).  Available  from:  http://www.clinicaltrials.gov/ct2/show/
NCT00574275. Accessed September 21, 2011.